NexaBiome
Chris Bindon is an accomplished professional in the pharmaceutical and biotechnology sectors, currently serving as Chief Operating Officer at NexaBiome, previously known as Fixed Phage Ltd, since March 2021. In this role, Chris provides strategic leadership across various business functions, including manufacturing, quality assurance, and process improvement, while driving the global commercialization of proprietary platforms for antibacterial therapies. Prior experience includes positions at GSK, such as Production Manager, where Chris led continuous improvement initiatives and managed production processes for Penicillin G Fermentation. Additionally, Chris held roles at Reckitt Benckiser as an R&D Senior Associate and at GSK as Product Manager and Analytical Project Leader. Chris holds an Oxford Executive Finance Programme certificate and a B.Sc. in Chemical and Pharmaceutical Sciences from the University of Sunderland, along with a NEBOSH National General Certificate in Health and Safety Management.
This person is not in any teams
NexaBiome
NexaBiome's patented technology enables bacteriophages to be covalently attached to a wide variety of substrates; this gives them enhanced stability for use in a variety of applications which address two of the world's major challenges, antibiotic resistance and food supply and sustainability. By attaching specific bacteriophages to fish and animal feeds, we can reduce, augment or even substitute for antibiotics in the food chain. This lets us target both human and animal pathogens, such as E. coli, Listeria, Campylobacter, Salmonella, Streptococcus, Pseudomonas, Flavobacteria and others. As our bonded phage products can be stable for months or even years and are less sensitive to temperature and other environmental factors, they can be effectively shipped and applied in versatile formulations Bacteriophages also have many potential human applications when antibiotics fail. Phages are expert microbiome engineers and can specifically alter the bacterial microbiome of the human gut, skin, vagina, lung and other micro-environments. Microbiome engineering has important applications to irritable bowel syndrome, acne, bacterial vaginosis and bacterial lung diseases. Our ability to attach bacteriophages to micro- and nano-particles and to enhance their stability and active life span, can potentially enhance their effectiveness in these applications, whether as part of a probiotic supplement or as encapsulated powders/beads.